Catalyst
Slingshot members are tracking this event:
Marinus (MRNS) to Commence Phase 2 Study Evaluating Ganaxolone IV in Life-Threatening Epilepsy in H1 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MRNS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 01, 2017
Occurred Source:
http://ir.marinuspharma.com/releasedetail.cfm?ReleaseID=1035277
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Initiation, Ganaxolone Iv, Life-threatening, Epilepsy, Refractory Status Epilepticus (rse)
